Adds W-18 (4-chloro-N-1-2-(4-nitrophenyl)ethyl2piperidinylidenebenzenesulfonamide) to the schedule of controlled substances.
Summary
This bill amends New York’s Public Health Law to add W-18, a synthetic opioid-like substance, to Schedule I of the state’s controlled substances list. Schedule I substances are treated as having a high potential for abuse and no accepted medical use under state law. The bill is narrowly drafted and does not create a broader regulatory program; it simply classifies W-18 as a prohibited controlled substance.
By placing W-18 in Schedule I, the bill would make the manufacture, sale, possession, and other unauthorized handling of the substance subject to New York’s controlled substance enforcement provisions. The change would give law enforcement and prosecutors a clearer statutory basis to address W-18 if it appears in illicit drug markets, and it would align the state’s controlled substance schedule with emerging synthetic drugs that may not yet be explicitly listed.
Impact
The bill would amend section 3306 of the Public Health Law, specifically subdivision (b) of Schedule I, by adding W-18 as a new listed substance. This would bring W-18 under New York’s controlled substance prohibitions and penalties applicable to Schedule I drugs, affecting individuals, distributors, and any entities handling the substance without authorization. Because the bill takes effect immediately, the classification would become operative as soon as enacted.
Sentiment
There is no recorded committee transcript or vote history in the provided materials, so no direct debate or formal sentiment can be measured from the legislative record here. Based on the bill’s text and purpose, the measure appears to be a straightforward public health and enforcement action aimed at restricting a dangerous synthetic drug. The absence of amendments, opposition, or recorded votes suggests the bill was introduced in a technical, noncontroversial posture, though that cannot be confirmed from the available record.
Contention
No specific points of contention are documented in the provided materials. In bills of this type, the main issues that sometimes arise are whether the substance should be scheduled immediately, whether the classification is overbroad, and whether law enforcement needs the added authority to respond to emerging drugs. However, no speakers, committee concerns, or recorded votes are available here to show that any of those issues were actually disputed on this bill.